Clinical Trial Search

Primary: Antibody Geometric Mean Concentrations (GMCs) Against the Vaccine Pneumococcal Serotypes 1, 4, 5, 6B, 7F, 9V, 14, 18C, 19F and 23F in the Unprimed Group — 0.06; 0.04…

Primary: Percentage of Participants Achieving American College of Rheumatology 20 Index (ACR20) — 19.5; 53.3; 48.0 Percentage of Participants — p=<0.001

Primary: Percent Change From Baseline in Fasting Low Density Lipoprotein Cholesterol (LDL-C) at Week 12 — 2.4; -52.0; -32.6 percent (%) change — p=<0.001

Primary: Snoring Severity Scale — -4.1 units on a scale — p=< 0.0001

Primary: The Total Blood Loss — 376.73; 339.81 ml

Primary: Salmeterol Protected Methacholine Challenge PC20 — 1.8; 1.7 mg/ml on log base 2 scale

Primary: Percentage of Subjects With Human Serum Bactericidal Activity (hSBA)≥1:4 — 84; 84; 84; 7 Percentage of subjects

Primary: Percentage of Participants With JE Seroprotection Before and Following a Booster Dose of IMOJEV Given One Year After Primary Immunization — 93.5; 100.0 Percentage of…

Primary: Percentage of Participants Who Achieve Sustained Virologic Response 12 Weeks Post-treatment (SVR12) — 97.6 percentage of participants

Primary: Morbidity - Number of Participants With Residual Shoulder Abduction Deficit — 276; 200 Participants

Primary: Primary Intra-operative Blood Loss — 100.00; 65.00; 142.80; 100.00 mL

Primary: Percentage of Participants With Sustained Virologic Response (SVR) 12 Weeks After Discontinuation of Therapy (SVR12) (Primary Study) — 96.2 percentage of participants…

Primary: Change in Non-calcified Plaque Volume in the Coronary Arteries Assessed by MDCTA From Baseline to 30 Months — 0; 0 mm^3

Primary: Disease-free Survival: Any Recurrence, Contralateral Breast Cancer, Second Primary Cancer, Death From Any Cause Prior to Recurrence or Second Primary Cancer — 80.1…

Primary: Treatment Emergent Adverse Events (AEs) up to 7 Days After Permanent Study Drug Discontinuation — 29; 26 Participants